Sarah A. Martin
Charterhouse Square
London, ENG EC1M6BQ, United Kingdom
London, ENG EC1M6BQ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
The DNA mismatch repair protein, MSH6 is a novel regulator of PD-L1 expression.
Journal: Neoplasia (New York, N.Y.)
Published: April 07, 2025
"Sick note culture" doesn't exist, it's toxic politics and our NHS that are failing us.
Journal: BMJ (Clinical research ed.)
Published: June 21, 2024
Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma.
Journal: iScience
Published: April 18, 2024
DNA mismatch repair deficient cancer - Emerging biomarkers of resistance to immune checkpoint inhibition.
Journal: The international journal of biochemistry & cell biology
Published: July 03, 2023
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma.
Journal: Cancers
Published: April 14, 2022
Statin Treatment as a Targeted Therapy for APC-Mutated Colorectal Cancer.
Journal: Frontiers in oncology
Published: February 22, 2022
Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy.
Journal: Communications biology
Published: August 23, 2021
The emerging relationship between metabolism and DNA repair.
Journal: Cell cycle (Georgetown, Tex.)
Published: April 20, 2021
Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.
Journal: Cell death & disease
Published: February 18, 2021
Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer.
Journal: Cell death & disease
Published: December 14, 2020
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Journal: Investigational new drugs
Published: September 14, 2020
Last Updated: 09/26/2026